Business
Neurochem announces appointment of John Bernbach to Board of Directors
Neurochem announces appointment of John Bernbach to Board of Directors.
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nLAVAL, QC, Jan. 16 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM)\nannounced today the appointment of Mr. John Bernbach to the Company's Board of\nDirectors.\n\n\nJohn Bernbach is the president and founder of NTM (Not Traditional\nMedia) Inc., a company that provides advisory services to marketers looking\nfor integrated alternative media solutions to more effectively reach and\nimpact target audiences.\n\n\n\"John is a world leader in advertising and marketing and we are very\npleased that he has agreed to join Neurochem's Board of Directors,\" said\nDr. Francesco Bellini, Chairman, President and CEO of Neurochem. \"His vast\nexperience and expertise in branding, marketing and advertising strategies\nwill serve Neurochem well as the Company prepares for the potential\ncommercialization of its product candidates.\"\n\n\nPrior to founding NTM Inc., John Bernbach was chairman and CEO of The\nBernbach Group, an executive management consulting business. From 1995 to\n2000, he served as director, and then chairman and CEO of North American\nTelevision based in the United States, which was successfully sold to the USA\nNetwork in 2001. Of his 28 years in the advertising business, 22 were spent\nwith Doyle Dane Bernbach, which he led into a merger with Needham Harper\nWorldwide and BBDO, creating the Omnicom Group, one of the largest, most\nprofitable communications groups in the world. He served as President and COO\nof DDB Needham Worldwide for eight years.\n\n\nAbout Neurochem\n\n\nNeurochem Inc. is focused on the development and commercialization of\ninnovative therapeutics to address critical unmet medical needs. Eprodisate\n(KIACTA(TM) - formerly FIBRILLEX(TM)) is currently being developed for the\ntreatment of Amyloid A (AA) amyloidosis, and is under regulatory review for\nmarketing approval by the U.S. Food and Drug Administration and European\nMedicines Agency. Tramiprosate (ALZHEMED(TM)), for the treatment of\nAlzheimer's disease, is currently in Phase III clinical trials in both North\nAmerica and Europe and tramiprosate (CEREBRIL(TM)), for the prevention of\nHemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a\nPhase IIa clinical trial.\n\n\nTo Contact Neurochem\n\n\nFor additional information on Neurochem and its drug development\nprograms, please call the North American toll-free numbe...